An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

I loved living in Portland, Oregon, in college and my early 20s — I thought I'd stay there forever.But a temporary move to Baker City, a small town in rural Oregon, shifted my mindset.I moved there ...

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...

More than 5 million Americans struggle with opioid use disorder, a physical addiction entwined with America’s health crisis, ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...